摘要
自1991年建立首批伦理委员会,我国伦理事业在新药临床试验中作用越来越强。我国伦理委员会借助亚太地区民间的伦理委员会审查能力发展行动战略认证系统进一步发展。本文就我国目前伦理委员会审查能力发展行动战略(SIDCER)认证现状进行分析。
China′s ethic committee has played an increasingly significant role in clinical trials of new drugs since the establishment of the first batch of Institutional Review Boards in 1991.The Strategic Initiative for Developing Capacity in Ethical Review （SIDCER） of our country′s Insti-tutional Review Boards with those in Asia -Pacific area has made enor-mous strides.Status of our homeland′s ethics committee SIDCER recog-nition was analyzed in this paper.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第4期381-382,共2页
The Chinese Journal of Clinical Pharmacology
关键词
伦理委员会
伦理委员会审查能力发展行动战略
institutional review board
Strategic Initiative for Developing Capacity in Ethical Review
